Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies
Cells · 2024
DOI: 10.3390/cells13110928 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Anna Roshani Dashtmian und 2 weiteren Autor:innen. Beteiligte Einrichtung: NextGen Precision Health, University of Missouri, Columbia, MO 65211, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Aging. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, national institute of health, National Institute on Aging/National Institute of Health.
Abstract (Originalsprache)
Amyotrophic Lateral Sclerosis (ALS) is a group of sporadic and genetic neurodegenerative disorders that result in losses of upper and lower motor neurons. Treatment of ALS is limited, and survival is 2–5 years after disease onset. While ALS can occur in younger individuals, the risk significantly increases with advancing age. Notably, both sporadic and genetic forms of ALS share pathophysiological features overlapping hallmarks of aging including genome instability/DNA damage, mitochondrial dysfunction, inflammation, proteostasis, and cellular senescence. This review explores chronological and biological aging in the context of ALS onset and progression. Age-related muscle weakness and motor unit loss mirror aspects of ALS pathology and coincide with peak ALS incidence, suggesting a potential link between aging and disease development. Hallmarks of biological aging, including DNA damage, mitochondrial dysfunction, and cellular senescence, are implicated in both aging and ALS, offering insights into shared mechanisms underlying disease pathogenesis. Furthermore, senescence-associated secretory phenotype and senolytic treatments emerge as promising avenues for ALS intervention, with the potential to mitigate neuroinflammation and modify disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NextGen Precision Health, University of Missouri, Columbia, MO 65211, USA.
- NextGen Precision Health, Department of Physical Medicine and Rehabilitation, University of Missouri, Columbia, MO 65211, USA.
ORCID-Profile: William David Arnold
Förderung
- NIA NIH HHS
- national institute of health
- National Institute on Aging/National Institute of Health
Zitieren
APA
Dashtmian, A. R., Darvishi, F. B., & Arnold, W. D. (2024). Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies. Cells. https://doi.org/10.3390/cells13110928
Vancouver
Dashtmian AR, Darvishi FB, Arnold WD. Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies. Cells. 2024. doi:10.3390/cells13110928
BibTeX
@article{Dashtmian2024,
author = {Dashtmian, Anna Roshani and Darvishi, Fereshteh B and Arnold, William David},
title = {Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13110928}
}
EUVIMED